Cefepime has recently drawn much attention, due mostly to a meta-analysis reported by Yahav et al. (3). They observed higher all-cause mortality for cefepime than for other betalactam antibiotics (risk ratio, 1.26; 95% confidence interval [CI], 1.08 to 1.49) and described neurotoxic adverse effects and inadequate in vivo antimicrobial efficacy as plausible reasons for increased mortality.
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Chin and Seo question whether breakpoint MICs for cefepime should be reassessed for organisms other than P. aeruginosa. In particular, they ask whether a subgroup analysis excluding P. aeruginosa or Acinetobacter spp. allows us to generalize a change in breakpoints for all gram-negative bacilli.
Breakpoints should be reassessed when new mechanisms of antibiotic resistance are detected at some time after the breakpoints were originally determined (5) . With respect to gramnegative organisms other than P. aeruginosa, a number of mechanisms of antibiotic resistance have been discovered which elevate the MICs of cefepime. Foremost among these are a variety of beta-lactamases which can hydrolyze cefepime, thereby compromising its activity (2) . The MIC for at least 10% of extended-spectrum beta-lactamase (ESBL)-producing klebsiellae, for example, is 8 g/ml (3), which is precisely the MIC of interest in this discussion.
Reevaluation of breakpoints should be via evaluation of clinical data and pharmacokinetic/pharmacodynamic (PK/PD) data (5). Our clinical data showed that 56.3% of patients with a bloodstream infection due to a gram-negative organism for which the cefepime MIC was 8 g/ml died, compared to 24.1% of those infected with an organism for which the cefepime MIC was Ͻ8 g/ml (1). Our original purpose was to study gram-negative bacilli in toto rather than subgroups. However, the subgroup of P. aeruginosa dominates this discussion because P. aeruginosa is the most common organism for which the cefepime MIC is 8 g/ml. Formal statistical analysis of organisms other than P. aeruginosa is impossible because of small numbers. With respect to the Enterobacteriaceae, only six patients had a bloodstream infection with an organism for which the MIC was 8 g/ml or higher. Of those infected with an organism for which the cefepime MIC was 8 g/ml, two survived and one died. (The patient who died had a polymicrobial infection with Enterobacter cloacae, for which the cefepime MIC was 8 g/ml, and P. aeruginosa, for which the cefepime MIC was 1 g/ml).
Evaluation of PK/PD data has suggested that a cefepime dosing regimen of 1 to 2 g every 12 h risks a suboptimal probability of attaining important PK/PD targets (1). These targets are not specific for P. aeruginosa but are shared by the Enterobacteriaceae (1). Chin and Seo cite the study by Roos et al. (4) in their letter. The analysis by Roos et al. (4) in fact showed that the probability of target attainment for any gram-negative organism for which the cefepime MIC is 8 g/ml is less than 30% when 1 to 2 g of cefepime is administered every 12 h. This finding supports the concept that it is inappropriate to interpret a cefepime MIC of 8 g/ml to indicate susceptibility for any organism.
Certainly, it would be optimal for a large amount of clinical data to be available to support breakpoint revisions. In a case where clinical data are sparse, if the PK/PD data are compelling for the inadequacy of a dosing regimen for a certain MIC, it is appropriate either to change breakpoints based on the PK/PD analysis or to screen for the presence of mechanisms of resistance that would increase the MIC (5). We do not believe that screening for mechanisms of resistance solves the issue in this circumstance. We observed 11 patients infected with ESBL-producing Enterobacteriaceae. Mortality data were available for 10 of these patients, and 50% died. Importantly, 8 of these 10 patients had infections caused by isolates that would currently be reported as susceptible on the basis of the cefepime MIC (MIC Յ 8 g/ml). The majority of ESBL-producing organisms in our study were species of Enterobacter, a genus for which ESBL detection methods are not widely available. Thus, if diagnostic microbiology laboratories cannot aggressively test for ESBL production, then these cases of hidden resistance will go undetected by the microbiologist and the clinician, with the potential for untoward consequences. For this reason alone, we feel that cefepime breakpoints for Enterobacteriaceae should be lowered, removing the risk of organisms with hidden ESBLs resulting in MICs that PK/PD analyses suggest would not be adequately achieved by commonly used cefepime doses. Breakpoint change for cefepime and the Enterobacteriaceae would remove this risk.
